Cerity Partners LLC Takes $210,000 Position in Abrdn Life Sciences Investors (NYSE:HQL)

Cerity Partners LLC bought a new position in Abrdn Life Sciences Investors (NYSE:HQL) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 15,608 shares of the company’s stock, valued at approximately $210,000.

Several other large investors also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC grew its holdings in shares of Abrdn Life Sciences Investors by 12.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 347,615 shares of the company’s stock valued at $4,335,000 after buying an additional 38,000 shares during the last quarter. 180 Wealth Advisors LLC grew its stake in Abrdn Life Sciences Investors by 5.3% during the 3rd quarter. 180 Wealth Advisors LLC now owns 114,724 shares of the company’s stock valued at $1,431,000 after purchasing an additional 5,725 shares during the last quarter. Shaker Financial Services LLC increased its holdings in shares of Abrdn Life Sciences Investors by 2.1% in the third quarter. Shaker Financial Services LLC now owns 66,528 shares of the company’s stock valued at $830,000 after purchasing an additional 1,342 shares during the period. Private Advisor Group LLC raised its stake in shares of Abrdn Life Sciences Investors by 78.9% in the third quarter. Private Advisor Group LLC now owns 35,046 shares of the company’s stock worth $435,000 after purchasing an additional 15,459 shares during the last quarter. Finally, RPO LLC raised its stake in shares of Abrdn Life Sciences Investors by 75.7% in the third quarter. RPO LLC now owns 327,042 shares of the company’s stock worth $4,078,000 after purchasing an additional 140,942 shares during the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Trading Up 1.0 %

Shares of NYSE HQL opened at $13.10 on Tuesday. Abrdn Life Sciences Investors has a 52 week low of $11.34 and a 52 week high of $14.37. The business’s 50 day moving average price is $13.45 and its 200 day moving average price is $13.12.

Abrdn Life Sciences Investors Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, February 22nd were issued a dividend of $0.39 per share. The ex-dividend date of this dividend was Wednesday, February 21st. This is an increase from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.30. This represents a $1.56 dividend on an annualized basis and a yield of 11.91%.

Insider Activity at Abrdn Life Sciences Investors

In other Abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. purchased 2,022 shares of Abrdn Life Sciences Investors stock in a transaction that occurred on Monday, April 22nd. The stock was bought at an average price of $12.88 per share, with a total value of $26,043.36. Following the acquisition, the insider now owns 2,738,992 shares of the company’s stock, valued at approximately $35,278,216.96. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have bought 224,993 shares of company stock worth $2,910,910. 10.06% of the stock is owned by company insiders.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.